REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Whole Live Micro-organism, Cell, Or Virus Containing > Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) > Eukaryotic Cell Eukaryotic CellEukaryotic Cell patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190040 - Recombinant p53 adenovirus methods and compositions Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct. observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals ... 08/16/07 - 20070190039 - Novel cell lines, and methods of preparation and use thereof The present invention provides, in some embodiments, hippocampal neuron-derived cell lines that display voltage-gated calcium channels of various types, including the N-type channels. Such mixed calcium channel activity is similar to that observed in the hippocampal neurons from which they were originally derived. The cells also can be differentiated into ... 08/09/07 - 20070184038 - Therapeutic uses for mesenchymal stromal cells Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as ... 08/09/07 - 20070184037 - T cell immune response inhibitor The present invention discloses a T-cell immune response inhibitor. The T-cell immune response inhibitor supplied in the present invention comprises a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen; or it comprises a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine expression protein ... 08/09/07 - 20070184036 - Isolated cd4+ t cells defined by cmrf-35 The present invention relates generally to a method for the treatment or prophylaxis of a condition which provokes, or is exacerbated by, an immunological response. The present invention further enables methods of diagnosis of conditions which provoke, or are exacerbated by, an immunological response. The present invention further provides therapeutic ... 08/02/07 - 20070178077 - Method for in vitro preconditioning of myoblasts before transplantation Methods of pretreating healthy donor's myoblast cultures with growth or trophic factors on transplantation into subjects suffering from myopathic conditions such as muscular dystrophy. Compositions comprising myoblasts and fusion-promoting metalloproteases can be transplanted. Alternatively, myoblasts can be transplanted along with an agent inducing the expression of a fusion-promoting metalloprotease, or ... 08/02/07 - 20070178076 - Porous membrane device that promotes the differentiation of monocytes into dendritic cells Dendritic cells (DCs) for research and clinical applications are typically derived from purified blood monocytes that are cultured in a cocktail of cytokines for a week or more. Because it has been suggested that these cytokine-derived DCs may be deficient in some important immunological functions and might not accurately represent ... 08/02/07 - 20070178075 - Side population cells in cardiac repair It has been discovered that side-population cells induce cardiac tissue repair of infarcted myocardium. Provided herein are methods directed to treatment of cardiac injury using side-population cells. ... 07/26/07 - 20070172467 - Regeneration of endogenous myocardial tissue by induction of neovascularization This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder. This invention further provides the instant ... 07/26/07 - 20070172466 - Method of replenishing cells damaged by treatment for cancer A method of replenishing cells damaged by treatment for cancer comprising removing a sample of peripheral blood containing CD34+ pluripotent adult stem cells from a primate mammal, controllably expanding the cells without differentiation at a rate which produces an expansion factor of at least seven times within seven days while ... 07/19/07 - 20070166293 - Method for growing stem cells A method for growing stem cells comprising the steps of a providing stem cells with supporters said supporters being genetically modified in order to provide externally regulatable interactions between the supporters and the stem cells; supporters and stem cells are interchangeable upon genetic modification and interaction; applying an external signal ... 07/19/07 - 20070166292 - System for exsanguinous metabolic support of an organ or tissue An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion ... 07/19/07 - 20070166291 - Cell preparation A method for transduction of cells with a genetic construct and selection of genetically modified cells, the method comprising performing the transduction and selection in a closed system. ... 07/12/07 - 20070160588 - Treatment of peripheral vascular disease using postpartum-derived cells Compositions and methods of using cells derived from postpartum tissue such as the umbilical cord and placenta, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular ... 07/12/07 - 20070160587 - Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As ... 07/12/07 - 20070160586 - Methods for extending the replicative lifespan of cells The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured ... 07/12/07 - 20070160585 - Remedy for prion disease and method of producing the same It is intended to provide a drug which is efficacious in treating a prion disease and has a high safety. A remedy for a prion disease which contains a mesenchymal stem cell as the active ingredient and a method of producing the same. A remedy for a prion disease which ... 07/05/07 - 20070154465 - Stem cell therapy for retinal disease Method of treating retinal disease by intravitreally injecting defined cytokine-transfected stem cell population; adipose-derived stem cell comprising transient wound-healing trangenes; defined homogeneous and heterogeneous populations of cytokine-transfected adipose-derived stem cells; method of treating retinal disease involves step of laser-inducing retinal injury followed by intravitreally injecting a population of stem cells ... 07/05/07 - 20070154464 - Methods for screening for agents capable of modulating t lymphocyte function in response to a herpes simplex virus-infected cell Disclosed are methods for screening an agent for activity in modulating a T lymphocyte. The methods generally comprises contacting a HSV US3-expressing cell with a T lymphocyte in the presence or absence of the agent and monitoring a physiological change associated with CTL function to determine whether the agent modulates ... 06/28/07 - 20070148145 - Protein modulators of resistance to alkylating agents There is disclosed a method for identifying a therapeutically responsive phenotype, as distinguished, e.g. from an alkylating agent resistant phenotype in a cell, which method may be used to evaluate the likelihood of successful outcome of treating a tumor cell with an alkylating agent. The method is directed to the ... 06/28/07 - 20070148144 - Gene-enhanced tissue engineering Provided are mammalian cells comprising a recombinant sonic hedgehog (SHH) gene such that a recombinant SHH protein can be expressed by the cell. Also provided are matrices suitable for applying to a tissue defect. Additionally provided are tissue regeneration compositions. Methods of regenerating tissue at the site of a tissue ... 06/21/07 - 20070141038 - Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases. ... 06/14/07 - 20070134219 - Method and composition for producing a cellular allogeneic vaccine The present invention relates to a method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, comprising the following steps: isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and modifying the ... 06/14/07 - 20070134218 - Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells Methods of inducing the expression of a proteoglycan such as aggrecan in a cell are described. A method is described which includes transfecting a cell with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. The LIM mineralization protein can be ... 06/14/07 - 20070134217 - Plasmids, their derivatives and fragments, their methods of manufacture and application A method is described of obtaining a plasmid contained in a difficult to separate, heterogenous plasmid DNA fraction, particularly one containing various plasmids of similar sizes. Another aspect of the present invention are new plasmids obtained via the method according to the present invention, their derivatives and/or fragments, as well ... 06/14/07 - 20070134216 - Bone cell delivery device Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. ... 06/14/07 - 20070134215 - Method of inducing the differentiation of stem cells into myocardial cells For a method of inducing differentiation of cardiomyocytes from stem cells, a method is provided to induce efficiently and selectively differentiation of cardiomyocytes by such a method in which the stem cells are cultured to induce differentiation into cardiomyocytes in the presence of a substance that inhibits BMP signaling. ... 06/14/07 - 20070134214 - Inactivated host cell delivery of polynucleotides encoding immunogens Provided herein methods for in vivo delivery of an immunogen. In particular, the methods comprise administering an inactivated host cell to a mammal, wherein the host cell comprises a polynucleotide encoding an immunogen. After administration, the immunogen is then expressed in vivo by the mammal. ... 06/14/07 - 20070134213 - Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration The present invention is based on the capacity of the Olfactory Ensheathing Glia (OEG) to foster axonal regeneration in the adult mammalian central nervous system (CNS). This specific capacity is probably due to a combination of several factors, such as the molecular composition of cellular membrane and/or the capacity to ... 06/14/07 - 20070134212 - Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells Foreign cells can be grown in fetal non-mammalian hosts for the production of transplant organs and tissues, the development of new therapeutic agents, and the production of biological factors and drugs. Tissue-specific injury to fetal host target cells is carried without substantial injury to the maternal host or foreign cells, ... 06/07/07 - 20070128177 - Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders The present invention provides recombinant adeno-associated virus (rAAV) vectors encoding a tumor necrosis factor (TNF) antagonist and methods using these vectors to reduce levels of TNF in a mammal. The invention also provides methods of using these rAAV vectors in palliating TNF-associated disorders. ... 06/07/07 - 20070128176 - Stem cells of the islets of langerhans and their use in treating diabetes mellitus Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular ... 05/31/07 - 20070122396 - Morphogenic proteins and stimulatory factors in gene therapy Gene therapy methods for tissue formation, repair and regeneration using nucleic acids encoding morphogenic proteins and morphogenic protein stimulatory factors (MPSFs) are provided. ... 05/31/07 - 20070122395 - Genetic and pharmacological regulation of antidepressant-sensitive biogenic amine transporters through pkg/p38 map kinase The invention relates to the observation that the p38 mitogen-activated protein kinase pathway is an important regulator of biogenic amine transporter (BAT) function. By using modulator of p38 MAPK, one can alter BAT function in a specific manner. This recognition of the pathway and its interaction with the serotonin transporter ... 05/31/07 - 20070122394 - Compositions and methods for liver growth and liver protection The present invention provides pharmaceutical compositions and methods for liver proliferation and protection. Specifically useful are VEGFR modulating agents capable of promoting liver growth. Disclosed compositions and methods may be useful for promoting proliferation or treating pathological conditions in other organs of significant biological functions. ... 05/31/07 - 20070122393 - Immunophenotype and immunogenicity of human adipose derived cells The present invention encompasses methods and compositions for generating an isolated adipose tissue-derived stromal cell exhibiting a low level of immunogenicity. The present invention encompasses methods and compositions for reducing an immune response associated with transplantation by administering the recipient with an amount of adipose tissue-derived stromal cells effective to ... 05/31/07 - 20070122392 - Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel Embryonic stem cells are propagated in a hyaluronic acid. ... 05/31/07 - 20070122391 - Compositions and methods for non-targeted activation of endogenous genes The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment ... 05/24/07 - 20070116692 - Host cells obtained by introducing and expressing vhl gene in cancer cells or embryonic stem cells The present invention relates to host cells that can function as neurons which are obtained by introducing and expressing von Hippel-Lindau gene in cancer cells, such as neuroblastoma cells and anaplastic oncocytes derived from the nerve system, or embryonic stem cells. The obtained hosts that have grown in vitro are ... 05/24/07 - 20070116691 - Conditionally immortalized long-term stem cells and methods of making and using such cells Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse ... 05/24/07 - 20070116690 - Method for the generation of antigen-specific lymphocytes The invention provides systems and methods for the generation of lymphocytes having a unique antigen specificity. In a preferred embodiment, the invention provides methods of virally infecting cells from bone marrow with one or more viral vectors that encode antigen-specific antibodies for the production of, for example B cells and ... 05/24/07 - 20070116689 - Lim mineralization protein splice variants The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising splice variants of nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation ... 05/24/07 - 20070116688 - Methods of organ regeneration The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type ... 05/24/07 - 20070116687 - Method of modulating cellular transmigration and agents for use therein The present invention relates generally to a method of modulating cellular transendothelial migration and to agents useful for same. More particularly, the present invention relates to a method of modulating leukocyte extravasation by modulating an endothelial cell intracellular ERK (extracellular regulated kinase)-dependent signalling mechanism. The method of the present invention ... 05/24/07 - 20070116686 - Method for separating precursor cells producing gabaergic neuron alone To treat epilepsy or schizophrenia by transplanting precursor cells of GABAergic neurons into a region where GABAergic neurons are lost or decreased in the brain of a patient suffering from the disease, it is intended to provide a method for separating a precursor cell of GABAergic neuron in an adult ... 05/17/07 - 20070110736 - Buffer solution for electroporation and a method comprising the use of the same The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using an electric current and to a method for introducing biologically active molecules into animal or human cells using an ... 05/17/07 - 20070110735 - Methods for regulating angiogenesis and vascular integrity using trk receptor ligands The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ... 05/17/07 - 20070110734 - Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering lymphoid cells such as natural killer (NK) cells ... 05/17/07 - 20070110733 - Compositions and methods for stem cell delivery This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cell, methods of production, and kits. ... 05/10/07 - 20070104699 - Compositions for and methods of granzyme b inhibition The present invention is related to the discovery that serpina3n, a secreted protein, binds to and inhibits granzyme B activity. The invention thus provides cells that include a polynucleotide encoding a granzyme B inhibitory serpin, pharmaceutical compositions including a granzyme B inhibitory serpin or a polynucleotide encoding a granzyme B ... 05/10/07 - 20070104698 - Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease This invention relates to the design and construction of a gene encoding an encephalogenic epitope of proteolipid protein (PLP), design and construction of a gene encoding an encephalogenic epitope of myelin based protein (MBP), to methods of expression of a PLP epitope, to methods of expression of a MBP epitope, ... 05/10/07 - 20070104697 - Adipose tissue derived stromal cells for the treatment of neurological disorders The present invention relates to a treatment of neural injury and neurodegenerative diseases. Also included in the present invention is the use of adipose tissue derived stromal cells for the treatment of neural injury (stroke, traumatic brain injury, spinal cord injury) and neurodegeneration (i.e. Parkinson's disease). ... 05/10/07 - 20070104696 - Use of cell lines to produce active therapeutic proteins This invention relates to the production of proteins, including therapeutic plasma proteins, by virally-immortalized hepatocyte cell lines and by other eukaryotic cells, as well as to the use of such proteins for screening and therapy, as well as to nucleic acids, vectors, and transformed or transfected cells that carry the ... 05/03/07 - 20070098704 - Method of repairing tissue of a mammal Method of treating disease or repairing tissue with compositions comprising mammalian peripheral blood stem cells, preferably CD34+/CD38− cells, and preferably peripheral blood stem cells resulting from TVEMF-expansion. ... 05/03/07 - 20070098703 - Methods for using adipose-derived cells for healing of aortic aneurysmal tissue The present invention encompasses methods and apparatus for minimizing the risks inherent in endovascular grafting for aneurysm repair. The invention includes tracking a delivery means into an aneurismal site and deploying a stent graft in the aneurysmal site along side the delivery means. Next, adipocytes derived from adipose tissue are ... 05/03/07 - 20070098702 - Recombinant protein polymer vectors for systemic gene delivery The present invention relates to genetically engineered non-viral vectors for delivering a nucleic acid such as a therapeutic gene to a target cell. The vectors are suitable for systemic administration to an animal. In the simplest embodiment the non-viral vector is a nucleic acid-binding protein-based polymer (NABP) having at least ... 05/03/07 - 20070098701 - Methods for enhancing survival and/or proliferation of neural stem cells and neurite extension enhancers therefor pharmaceutical compostions containing neural stem cells assay methods and screening methods Problems to be Solved Methods for enhancing survival and/or proliferation of neural stem cells and pharmaceutical compositions containing neural stem cells prepared by such methods, together with methods for assaying factors enhancing survival and/or proliferation of neural stem cells and methods for screening for such factors. Means for Solving the ... 05/03/07 - 20070098700 - Synthetic mammalian retotransposon gene The invention relates to synthetic transposon and retrotransposon genes that exhibit higher levels of expression relative to natural transposon and retrotransposon genes. The invention further relates to transposons and retrotransposons comprising such synthetic genes. ... 04/26/07 - 20070092500 - Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α). ... 04/26/07 - 20070092499 - Method for changing genetic properties of eukaryotic organism The invention provides a method for changing the genetic properties of an eukaryotic organism by suppression of expression of a target gene. Proposed method can be used in gene-therapy in medicine, agriculture, or industrial biotechnology. Genetic properties of an eukaryotic organism are changed by gene-specific silencing of a selected gene ... 04/26/07 - 20070092498 - Methods of diagnosing, prognosing and treating breast cancer The protein pRb2/p130 represses expression of the ER-α gene. Blocking pRb2/p130 expression or altering ER-α gene methylation to alter pRb2/p130 complex binding allows transcriptional activity of the ER-α gene to be restored. Detecting and regulating the methylation state of the ER-α gene, optionally together with detecting and regulating pRb2/p130 multimolecular ... 04/19/07 - 20070086989 - Prosthetic grafts An improved prosthetic graft for the bypass, replacement or repair of vessels and organs that are in contact with blood flow is disclosed. The prosthetic graft includes a porous prosthetic implant and adherent cells adhered to the outer surface of the implant. The adherent cells are transfected with at least ... 04/19/07 - 20070086988 - Insulin expressing human pancreatic islet cell line capable of reversibly proliferating and use thereof A reversibly immortalized human pancreatic islet cell line containing an hTERT gene and an SV40T gene each interposed between a pair of LoxP sequences, characterized in that it is capable of producing insulin and enhancing expression of insulin after excising the hTERT gene and the SV40T gene, in particular, NAKT-13 ... 04/12/07 - 20070081983 - Isolation of smooth muscle cells and tissue-engineered vasculature containing the isolated cells The present invention is directed to a method of isolating smooth muscle cells or progenitors thereof from a mixed population of cells. A preparation of isolated smooth muscle cells or progenitors thereof, where the smooth muscle cells or progenitors thereof constitute at least 90% of the preparation, is also disclosed. ... 04/12/07 - 20070081982 - Multiple rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns The present invention provides compositions and methods suitable for expressing y-x multiple-RNAi agents against an allele or alleles of interest in cells, tissues or organs of interest in vitro and in vivo so as to treat diseases. ... 04/12/07 - 20070081981 - P18 in stem cell manipulations A method to increase self-renewal of an undifferentiaded human stem cell culture or cell line, by reducing or eliminating the presence of the protein “p18”. ... 03/29/07 - 20070071736 - Method and apparatus for installation of dental implant An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ. ... 03/29/07 - 20070071735 - Method and apparatus for installation of dental implant An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ. ... 03/29/07 - 20070071734 - Arpe-19 as platform cell line for encapsulated cell-based delivery ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; ... 03/22/07 - 20070065422 - Induction of immune tolerance by sertoli cells The subject invention pertains to methods to enhance the therapeutic effects of cell therapy in various diseases and disorders. More particularly, the present invention provides methods of inducing systemic immune tolerance, thereby reducing or eliminating the need for systemic immunosuppression, by administering isolated Sertoli cells to an individual in need ... 03/22/07 - 20070065421 - Inducing expression of puma to reduce joint inflammation in the treatment of arthritis It has been discovered the BH3-only proapoptotic Bcl-2 proteins like PUMA (the p53 upregulated modulator of apoptosis) can be activated in fibroblast-like synoviocytes present in the joints of subjects with rheumatoid arthritis. This bypasses the p53 apoptotic pathway, which normally clears FLS fomr the joints, but is often defective in ... 03/15/07 - 20070059294 - Therapeutiv preparation for hematopoietic disease The present invention provides therapeutic formulations for hematopoietic diseases comprising as effective ingredient, synoviolin which is reported to be isolated as a synovial cell protein and its gene, and therapeutic methods and such comprising the step of administering the protein or polynucleotide. The present invention also provides as models of ... 03/08/07 - 20070053891 - Snail, a new marker for tumour invasion and target protein of new antitumoral compounds The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumour cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumour marker, indicative of ... 03/08/07 - 20070053890 - Canine embryonic stem cells The invention relates to canine embryonic stem cells, methods of cultivation and propagation of the cells, and production of differentiated cells. The embryonic stem cells may be obtained by isolating a canine embryo, culturing the embryo in the presence of a feeder layer and one or more proliferation agent, removing ... 03/08/07 - 20070053889 - Il-10 gene transfer to peripheral mononuclear cells The present invention to methods for producing mononuclear cells overexpressing IL-10. The method comprises the ex vivo introduction of an expression construct comprising a nucleotide sequence encoding a polypeptide having IL-10 activity into peripheral blood mononuclear cells of a subject. The thus obtained peripheral blood mononuclear cells have an altered ... 03/01/07 - 20070048294 - Method for inhibiting telomerase activity The present application discloses a purified covalently closed antisense molecule, which specifically inhibits expression of human telomerase by specifically binding to nucleic acid encoding human telomerase. ... 03/01/07 - 20070048293 - Manipulation of pten in t cells as a strategy to modulate immune responses The present invention relates to compositions and methods for modulating the expression and/or activity of PTEN in T cells, regulatory T cells, and CD4 T cells. The manipulation of PTEN provides a means for regulating an immune response. ... 02/22/07 - 20070041957 - Stimulation of cellular regeneration and differentiation in the inner ear The present invention provides methods for stimulating the formation of inner ear cells, including inner ear sensory hair cells and inner ear support cells. The methods of the present invention damage and/or kill inner ear cells, and stimulate the formation of new, inner ear cells. ... 02/15/07 - 20070036775 - Method of modulating or examining ku70 levels in cells A method of predicting whether cells would respond to therapies which are mediated through Bax-regulated apoptosis is disclosed. In one embodiment, the method comprises the step of: (a) examining the intensity of the expression of the Bax protein or mRNA in a cell relative to a control, and (b) based ... 02/15/07 - 20070036774 - Liver engrafting cells, assays, and uses thereof A substantially enriched mammalian hepatic liver engrafting cell population is provided. Methods are provided for the isolation and culture of this liver engrafting cell. The progenitor cells are obtained from a variety of sources, including fetal and adult tissues. The cells are useful in transplantation, for experimental evaluation, and as ... 02/15/07 - 20070036773 - Generation and application of universal t cells for b-all The present invention is directed to universal T cells and their use in treating diseases and other physiological conditions. More specifically, the present invention is directed to universal T cells and their use in treating treating B-lineage acute lymphoblastic leukemia (B-ALL) in particular and malignancy in general. The universal T ... 02/15/07 - 20070036772 - Directed in vitro differentiation of marrow stromal cells into neural cell progenitors The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels ... 02/15/07 - 20070036771 - Biologic device for regulation of gene expression and method therefor A system and device are provided which include a gene regulatory system controlling expression of one or more expression cassettes present in or released by the device, by emitting one or more stimulations. An expression cassette includes a regulatable transcription control element that is responsive to the emitted stimulations linked ... 02/15/07 - 20070036770 - Biologic device for regulation of gene expression and method therefor A system and device are provided which include a gene regulatory system controlling expression of one or more expression cassettes present in or released by the device, by emitting one or more stimulations. An expression cassette includes a regulatable transcription control element that is responsive to the emitted stimulations linked ... 02/15/07 - 20070036769 - Bmp pathway methods and compositions The present invention relates to mutant BMP intestinal stem cells (ISCs), with these mutant ISCs possessing an inactive Bmpr1a receptor in which BMP binding is substantially inhibited. The present invention relates to vectors which comprise mutant Bmpr1a nucleic acid sequences, whereby the vectors can be used to promote an increase ... 02/08/07 - 20070031392 - Delivery vehicle for recombinant proteins Recombinant nucleic acid molecules are constructed with a first sequence encoding a transgene under the control of regulatory sequences that direct expression of the transgene product in a hematopoietic stem cell, or a progenitor cell therefrom or cell differentiated therefrom. In one embodiment, the cell which expresses the transgene is ... 02/08/07 - 20070031391 - Neural stem cells and use thereof for brain tumor therapy The present invention is based upon a surprising finding that stem cells, more particularly neural stem cells, can migrate throughout a brain tumor and track metastatic brain tumor cells. The invention provides a method for treating brain tumors by administering genetically engineered neural stem cells in an individual affected by ... 02/08/07 - 20070031390 - Methods and compositions for site-specific genomic expression of nucleic acid sequences The present invention is directed to methods and compositions for site-specific genomic expression of nucleic acid sequences. ... 02/01/07 - 20070025975 - Oligodendrocyte determination genes and uses thereof The invention relates to methods and reagents for promoting the differentiation of oligodendrocytes from stem cells, by co-activating the Olig genes and the Nkx2.2 genes, and the use of the differentiated oligodendrocytes thus obtained in treating diseases, such as Multiple Sclerosis (MS). The invention also relates to the use of ... 02/01/07 - 20070025974 - Amylases producing an altered immunogenic response and methods of making and using the same The present invention provides novel amylase variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel amylase variants, host cells comprising DNA encoding novel amylase variants, as well as methods for making amylases less allergenic. In addition, the ... 01/25/07 - 20070020248 - Process for biological tissue The present invention provides an electrophoretic system, apparatus, and method of use thereof for the preparation of a tissue-derived bioprosthesis. ... 01/18/07 - 20070014775 - Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope ... 01/18/07 - 20070014774 - Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl ... 01/18/07 - 20070014773 - Compositions for regenerating defective or absent myocardium Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods ... 01/11/07 - 20070009501 - Squamous cell carcinoma antigens and use therefor The present invention relates to tumor antigens of the squamous epithelial carcinoma, nucleic acids encoding the same as well as antibodies directed against the same. The invention furthermore relates to methods for the generation of antigen presenting cells and T cells specific for such antigens. Eventually, the invention comprises diagnostic ... 01/11/07 - 20070009500 - Compositions and methods for the treatment of lysosomal storage disorders The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells. ... 01/11/07 - 20070009499 - Myoblast treatment of diseased or weakened organs Bioengineering the regenerative heart or other body organ in need of greater muscle mass or improved blood perfusion provides a novel treatment for organ weakness or failure. In the case of cardiac failure treatment, on May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465 ... 01/11/07 - 20070009498 - Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines Unique multifunctional nucleotide expression cassettes comprising a nucleotide sequence encoding a human protease driven by a glucose-regulatable promoter, a nucleotide sequence encoding human proinsulin having sites at its B-C and C-A junctions altered to permit cleavage by the human protease, and a CMV promoter driving the transcription of the nucleotide ... 01/11/07 - 20070009497 - Dendritic cell expanded t suppressor cells and methods of use thereof This invention relates to culture-expanded T suppressor cells and their use in modulating immune responses. This invention provides methods of producing culture-expanded T suppressor cells, which are antigen specific, and their use in modulating complex autoimmune diseases. ... 01/11/07 - 20070009496 - Method of growing myocardial cells The proliferation of cardiomyocytes is induced by expressing cyclin and CDK in the cardiomyocytes, and by suppressing the function or action of a Cip/Kip family protein or inhibiting the production of a Cip/Kip family protein. Among the Cip/Kip family proteins, it is preferable to suppress the function of p27KiP1 or ... 01/04/07 - 20070003533 - Inhibition of the beta3 subunit of l-type ca2+ channels The present invention provides reagents and methods for identifying inhibitors of the L-type Ca2+ channel β3 protein, which has been demonstrated to be involved in calcium signaling, insulin secretion, and glucose homeostasis. The invention also provides therapeutics and methods for treating a subject with one or more of diabetes, insulin ... 01/04/07 - 20070003532 - Novel mechanism for identifying drugs for the treatment of type ii diabetes Insulin resistance is a central feature of type II diabetes and other diseases, and may affect every tissue of the body, including the pancreatic beta cell. Insulin signaling is mediated by a complex network of diverging and converging pathways, with alternative proteins and isoforms at almost every step in the ... 01/04/07 - 20070003531 - Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic t lymphocytes The invention relates generally to methods for enhancing immunity by improving the survival of activated T cells comprising the administration to a cell or a subject in need thereof an effective amount of an inhbitor of JNK and/or AIF. In other aspects the invention relates to the administration of an ... 01/04/07 - 20070003530 - Cardiac muscle regeneration using mesenchymal stem cells Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. ... 01/04/07 - 20070003529 - Generating teeth from bone marrow cells The present invention is based on the discovery that teeth primordia can be generated using bone marrow cells and that bone marrow cells may be employed to generate teeth without the need for purification and expansion of a population of cells. ... 12/28/06 - 20060292132 - Neuroprotective effective compound The present application discloses a method of preventing degeneration of nerve, which includes: a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily or neurotrophic factor proteins operatively linked to a promoter; b) transfecting in vitro a population of ... 12/28/06 - 20060292131 - Chondrocyte therapeutic delivery system Methods and compositions for producing therapeutic agents using chondrocytes are provided. The genetically engineered chondrocytes can be used to express the therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes. ... 12/28/06 - 20060292130 - 2-o sulfatase nucleic acid compositions The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present ... 12/28/06 - 20060292129 - Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention ... 12/21/06 - 20060286083 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or ... 12/21/06 - 20060286082 - Systems and methods for generating biological material The invention relates to systems and methods for synthesizing biological material. ... 12/21/06 - 20060286081 - Conditioned cell culture medium, method to obtain the same and use of it for maintenance, proliferation and differentiation of mammalian cells The invention relates to a conditioned cell culture medium and a corresponding method to obtain it. The invention also refers to methods of using this cellconditioned medium for the maintenance, proliferation and differentiation of mammalian cells. The culture medium produced in accordance with the present invention is conditioned by the ... 12/21/06 - 20060286080 - Method for obtaining plasmid-dna by means of an aqueous biphasic system The invention relates to a process for isolation of plasmid DNA from biomass by means of an aqueous 2-phase system having a polymer component and a salt component, characterized in that the resuspension of the biomass employed, the alkaline lysis of the biomass, the neutralization of the alkaline lysis batch ... 12/14/06 - 20060280729 - Cellular therapy for ocular degeneration Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 ... 12/14/06 - 20060280728 - Trimeric ox40-immunoglobulin fusion protein and methods of use Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition comprising a trimeric OX-40 fusion protein and a pharmaceutically ... 12/07/06 - 20060275275 - Cells and methods for estimation of effects on neurological dysfunction The invention provides neuron-derived cells obtained by transfecting a receptor-expressing nucleic acid having an aryl hydrocarbon receptor gene, wherein outgrowth of neurites is not observed without adding a substance for the aryl hydrocarbon receptor, and outgrowth of neurites is observed by adding the substance for the aryl hydrocarbon receptor. The ... 12/07/06 - 20060275274 - Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome The present invention discloses Saposin-related homologous proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders. ... 11/30/06 - 20060269532 - Compositions and methods for the therapy and diagnosis of prostate cancer Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The ... 11/30/06 - 20060269531 - Apparatus for generating electrical pulses and methods of using the same A method and apparatus are provided for delivering an agent into a cell through the application of nanosecond pulse electric fields (“nsPEF's”). The method includes circuitry for delivery of an agent into a cell via known methods followed by the application of nanosecond pulse electric fields to said cell in ... 11/30/06 - 20060269530 - Rna interference compositions and methods The invention provides isolated nucleic acids. For example, the invention provides isolated nucleic acids having at least one strand with both sense and antisense sequences that are complementary to each other. The invention also provides isolated nucleic acids having at least one strand that is a template for both sense ... 11/30/06 - 20060269529 - Modified t lymphocytes and uses therefor Modified T lymphocytes that express a chimeric T cell receptor reactive with two or more different cell surface angiogenic marker are disclosed. The modified T lymphocytes are useful in methods in controlling angiogenesis and in therapeutic methods in controlling tumor growth. ... 11/30/06 - 20060269528 - Production detection and use of transformant cells A bioactive compound, or family of compounds, is biosynthesised by a cell using a plurality of enzymic activities. Host cells are provided that substantially lack the bioactivity, but possess at least a first one of the enzymic activities (or nucleic acid encoding a corresponding enzyme). The cells are transformed with ... 11/23/06 - 20060263343 - Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease An antigen-specific T-cell response to alloantigen, tissue-specific antigen (e.g., islet antigen or other autoantigens involved in autoimmune disease), or self (or host) antigen is detected at an early stage of graft rejection or recurrent autoimmunity. An increase in cytotoxic lymphocyte gene (CLG) expression in peripheral blood is a risk factor ... 11/23/06 - 20060263342 - Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines The invention relates to colon and prostate tumor associated antigen peptides obtainable from prostate specific G protein-coupled receptor (PSGR), six-transmembrane epithelial antigen of prostate (STEAP) and proteins encoded by genes found overexpressed in colon carcinoma cells, such as human 1-8D interferon induced transmembrane protein 2. The invention further relates to ... 11/16/06 - 20060257383 - Human skin equivalents expressing exogenous polypeptides The present invention relates generally to compositions for wound healing. More specifically, the present invention provides human skin equivalents engineered to express exogenous proteinase inhibitor polypeptides (e.g., TIMP-1 polypeptides) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods ... 11/16/06 - 20060257382 - Corneal cells expressing active agents and methods of use thereof The invention relates to methods of modifying cells of corneal tissue to express an active agent, to modified corneal tissue, to vectors utilised in such methods and to methods of xeno- and allo-transplantation utilising the modified corneal tissue. The method of modifying cells of corneal tissue to express an active ... 11/16/06 - 20060257381 - Method for transplanting lymphohematopoietic cells into mammal The present invention provides a method for transplanting lymphohematopoietic cells into a mammal, which comprises the step of injecting cells into a bone marrow cavity, and wherein the cells have an exogenous gene encoding a receptor that induces cell proliferation in response to ligand binding. By combining intra-bone marrow transplantation ... 11/16/06 - 20060257380 - Use of sirnas for gene silencing in antigen presenting cells The present invention relates to the use of small interfering RNAs (siRNAs) for silencing gene expression in antigen-presenting cells such as dendritic cells, in particular for immunomodulatory purposes. ... 11/09/06 - 20060251632 - Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject. ... 11/09/06 - 20060251631 - Treatment of joint disease, methods and apparatuses therefor The present application discloses compositions, methods and devices for treatment of degenerative cartilaginous structures of an arthritic joint, including articular cartilage and the meniscus. A composition can comprise chondrocytes expressing type II collagen and a biological macromolecule such as hyaluronic acid or a collagen. The chondrocytes can be obtained from ... 11/09/06 - 20060251630 - Encapsulated cell therapy Cell therapy comprises encapsulating a cell with an integrin or other cell interaction factor, for administration to a mammal. The cells may express a therapeutic transgene or the cells may be regenerative. ... 11/02/06 - 20060246044 - Methods for improving cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, ... 11/02/06 - 20060246043 - Cellular preparation The present invention provides a cellular preparation wherein cells capable of secreting biologically active factors such as hormones or proteins useful for patients can be retained in polyvinyl alcohol stably for a prolonged period of time and a production method of the cellular preparation, and a method for prevention and ... 10/26/06 - 20060239985 - Method of preparing cell for transplantation The invention features a method of producing cells for transplantation into myocardial tissue of a mammal and a method for treating a disorder using the cells. The method comprises the steps: (a) providing bone marrow stem cells that have not been immortalized; (b) culturing said bone marrow stem cells in ... 10/26/06 - 20060239984 - Promoter to il-18bp, its preparation and use The present invention relates to the promoter of interleukin-18 binding protein (IL-18BP), to its preparation and use. ... 10/19/06 - 20060233771 - Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands Methods for promoting dopaminergic neuronal development and producing neural cells having a dopaminergic phenotype are provided. Dopaminergic neural cells may be used for treating individuals having a neurodegenerative disease such as Parkinson's disease. Dopaminergic cells may be implanted into the brain of the individual, and/or dopaminergic neural development may be ... 10/19/06 - 20060233770 - Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or ... 10/12/06 - 20060228344 - Cell-containing preparations The present invention provides a cell-containing preparation comprising cells containing a DNA having a base sequence represented by SEQ ID NO:1 or 2, or a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO:1 or 2 under stringent conditions, and a fibrous protein. The cell-containing ... 10/12/06 - 20060228343 - Cardiac glycoside resistant non-immunogenic selection marker A recombinant Na+, K+-ATPase α1-subunit protein resistant to cardiac gIycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained b y alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid ... 10/12/06 - 20060228342 - Method for generating antigen-presenting cells Described is a method for the generation of antigen-presenting cells (APC), preferably bone marrow-derived dendritic cells (BMDC) or peripheral blood-derived dendritic cells, as antigen carrier having immunostimulatory properties for anti-infective treatment comprising the steps of (a) pulsing the APC with antigen and (b) treating the APC with a CpG oligonucleotide. ... 10/05/06 - 20060222636 - Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells The present invention includes compositions, methods and kits for non-nuclear transfer reprogramming an adult differentiated cell obtained from an adult tissue into an ES-like cell. The reprogrammed cell can be converted into an ES-like cell which can be re- or trans-differentiated into various differentiated cell types. The present invention further ... 10/05/06 - 20060222635 - Methods and compositions for selecting cells with increased potency The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present ... 09/28/06 - 20060216278 - Entrapped stem cells and uses thereof The invention relates to the stem cells, embryonic stem cells in particular. It has been found that, when these stem cells are entrapped such that their proliferation is inhibited, they produce material which inhibits the proliferation of other, non-entrapped cells, including stem cells and neoplastic and/or hyperproliferative, but otherwise normal ... 09/28/06 - 20060216277 - Insulin-producing bone marrow derived cells and methods of generating and using same Insulin-producing bone marrow derived stem cells, and methods of generating and using same to reduce blood glucose levels in individuals. ... 09/21/06 - 20060210544 - Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or ... 09/07/06 - 20060198829 - Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in ... 09/07/06 - 20060198828 - Methods and compositions for the inhibition of gene expression The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers. ... 08/31/06 - 20060193841 - Method for the treatment of parkinson's disease A method of treating Parkinson's Disease in patients exhibiting increasing resistance to the administration of L-dopa due to loss of aromatic L-amino acid decarboxylic activity in striatal neurons comprises transfection of the caudate and/or putamen regions with a viral vector encoding AADC. The vector preferably has a promoter system provided ... 08/31/06 - 20060193840 - Perivascular mesenchymal precursor cell induced blood vessel formation Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 ... 08/24/06 - 20060188491 - Use of nuclear material to therapeutically reprogram differentiated cells Methods are provided for therapeutically reprogramming differentiated cells with nuclear extracts from pluripotent stem cells to generate a pluripotent epigenetic state in the differentiated cells. Additionally, therapeutically programmed cells for therapeutic use in patients are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent ... 08/24/06 - 20060188490 - Transfection of blood cells with mrna for immune stimulation and gene therapy The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region ... 08/24/06 - 20060188489 - Methods and materials for increasing potency of cells Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent ... 08/17/06 - 20060182726 - Immunomodulating compositions, processes for their production and uses therefor The present invention discloses compositions and methods for antigen-specific suppression of immune responses, including primed immune responses. In particular, the invention discloses antigen-presenting cells, especially dendritic cells, whose level and or functional activity of CD40, or its equivalent, is impaired, abrogated or otherwise reduced, and their use for treating and/or ... 08/10/06 - 20060177428 - Vascular endothelial growth factor d (vegf-d) antibodies and vectors, and methods of use Isolated nucleic acid molecule comprising an antisense nucleic acid sequence which is antisense to a polynucleotide that encodes a VEGF-D polypeptide, vectors and host cells including the same. Also disclosed are methods of inhibiting VEGF-D function or expression in a mammal, for example, in treating cancer, comprising administering to the ... 08/03/06 - 20060171935 - Protecting cell therapy for neurological disorders including parkinson's disease The present invention provides compositions and methods for enhancing and improving cell therapies for neurological disorders including Parkinson's disease. Specifically, the present invention provides a cell or cells modified by viral vector compositions that allow for the over-expression and RNAi mediated knockdown of genes in vitro and in vivo. The ... 08/03/06 - 20060171934 - Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering lymphoid cells such as natural killer (NK) cells ... 08/03/06 - 20060171933 - Cell culture A method for culturing mammalian cells without the need for the addition of xenobiotic materials which promote mammalian cell culture, for example, serum or a pituitary extract and including methods for the production of cells for use in tissue engineering and the production of recombinant protein. ... 07/27/06 - 20060165668 - Genetically modified tumor cells as cancer vaccines The present invention provides methods and compositions for electroporation-mediated gene transfer to cancer cells. The transfected cancer cells are genetically modified to express one or more therapeutic proteins. In certain embodiments, the cancer cells are modified to express one or more cytokines capable of enhancing the immunogenicity of the transfected ... 07/27/06 - 20060165667 - Novel methods, compositions and devices for inducing neovascularization The invention provides methods of inducing neovascularization in a subject in need thereof. The invention further provides compositions, devices and implantable products generated from conditioned media, and in particular, from conditioned media from cultured umbilical cord populations. These compositions are useful for inducing neovascularization. The invention also provides methods of ... 07/27/06 - 20060165666 - Hemangioblast progenitor cells The invention relates to isolated hemangioblast cells. Hematopoietic and endothelial cells are postulated to be derived from a common progenitor, hemangioblast. While hemangioblast has been isolated retrospectively during embryonic stem cell differentiation, it has not been isolated from embryos or from bone marrow. Prospectively stable clonal cell lines have been ... 07/27/06 - 20060165665 - Immunomodulation using altered dendritic cells The invention relates to altered immune cells and their use in methods and compositions to alter the immune system in a mammal. More specifically, the invention is directed to the alteration of gene expression in antigen presenting cells such as dendritic cells (DC) and their use in various methods and ... 07/27/06 - 20060165664 - Method of inducing an enhanced immune response against hiv An efficient means of inducing an immune response against human immunodeficiency virus (HIV) utilizing specific prime-boost regimes is disclosed. The specific prime-boost regimes employ a heterologous prime-boost protocol employing recombinant adenoviral vectors of alternative and distinct serotypes comprising exogenous genetic material encoding a common HIV antigen. Vaccines administered into living ... 07/20/06 - 20060159670 - Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors Current sources of neural stem and progenitor cells for neural transplantation are essentially inaccessible in living animals. This invention relates to neural precursor cells (stem cells, progenitor cells or a combination of both types of cells) isolated from the olfactory epithelium of mammals that can be passaged and expanded, and ... 07/20/06 - 20060159669 - Novel uses of ppar modulators and professional apcs manipulated by the same The invention relates to a manipulated professional antigen presenting cell (APC) having increased expression of a CD1 type II molecule, preferably at least a CD1d molecule, relative to a control non manipulated cell. The invention further relates to the use of PPARg modulators in the preparation of a pharmaceutical composition ... 07/13/06 - 20060153821 - Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products Formulations comprising combinations of APCs and tumor cells and APCs and virally infected cells are disclosed. These formulations generally comprise hybridoma of at least one antigen presenting cell fused to either at least one tumor cell or at least one virally infected cell, or the products of co-cultures of antigen ... 07/13/06 - 20060153820 - Materials and methods relating to the production and maintenance of cell lines The invention provides methods for maintaining cell lines from primary cells, i.e. non-transformed cells, using expression of the signal transducer of activation and transcription (STAT). The methods are particularly suitable for the maintenance of B-cells. ... 07/06/06 - 20060147437 - Use of pigmented retinal epithelial cells for creation of an immune privilege site The present invention relates to a novel in vivo method for creation of a localized immunosuppressive environment in tissue. The method involves the transplanting of pigmented retinal epithelial cells into a mammal thereby producing a localized immunosuppressive environment. The transplanted pigmented retinal epithelial cells may also be used to produce ... 07/06/06 - 20060147436 - Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies ... 07/06/06 - 20060147435 - Methods for regulation of stem cells Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian ... 07/06/06 - 20060147434 - Different dendritic cell subsets It is intended to provide expired dendritic cells having characteristics of the following (E1) to (E3): (E1) not shifting into a mature type due to an action of a natural immune stimulant or a permanent immune potentiator;(E2) having the same shape as immature DC; and (E3) expressing IL-10. It is ... 06/29/06 - 20060140922 - Universal gm-csf expressing bystander human k562 cell line The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition. ... 06/29/06 - 20060140921 - Disimmortalizable mammalian chromaffin cell lines for cell therapy for pain Cloned disimmortalizable mammalian chromaffin cell lines that express chromaffin cell phenotype/genotype are disclosed. ... 06/29/06 - 20060140920 - Adenoviral vectors encoding an antibody fused to a cd4 extracellular domain Genetically modified cell implant comprising an exogenous nucleotide sequence coding for all or part of an antibody, method for the preparation of such an implant and its therapeutic use for the treatment or prevention of an acquired disease. The invention also concerns an adenoviral vector for the expression of one ... 06/22/06 - 20060134081 - Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell. The disclosure also ... 06/22/06 - 20060134080 - Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1+ ... 06/22/06 - 20060134079 - Implantable medical devices comprising isolated extracellular matrix Implantable devices containing extracellular matrix and methods of using the devices are provided. ... 06/22/06 - 20060134078 - Method for culturing neural stem cells using hepatocyte growth factor A medium containing hepatocyte growth factor (HGF) was shown to induce neurosphere formation. Furthermore, the addition of HGF to a culture medium containing FGF-2, EGF, or both increased both the size and number of newly formed neurospheres. Thus, the present invention relates to a growth medium comprising HGF for culturing ... 06/22/06 - 20060134077 - Electronic commerce system including customized catalog having encoded information The invention features methods for the treatment of diabetes by administering a IAP nucleic acid sequence to a subject. One method includes the steps of (a) providing one or more insulin-producing cells or one or more precursor cells capable of producing progeny cells that produce insulin; (b) transducing the cells ... 06/15/06 - 20060127377 - T cell receptors with enhanced sensitivity recognition of antigen The present invention relates to methods of treating an infectious, proliferative, or lymphocyte-mediated disease that involve providing a T cell receptor β chain (TCR β) having higher sensitivity recognition of antigen than a wild type TCR β chain and introducing the TCR β chain directly or indirectly to a subject ... 06/15/06 - 20060127376 - Methods and compositions for modulating apoptotic pathways The present invention relates to methods and compositions for modulating apoptotic pathways. In particular, the present invention relates to methods and compositions for inducing apoptosis in cancer cells. The present invention further relates to methods and compositions for identifying drugs that modulate apoptotic pathways. ... 06/08/06 - 20060121014 - Method of diminishing the symptoms of neurodegenerative disease A method of diminishing the symptoms of neurodegenerative disease in a patient is disclosed. In one embodiment, the method comprises the steps of: (a) identifying a patient with a neurodegenerative disease, (b) producing a cell culture, wherein the cell culture comprises cells with induced antioxidant response element (ARE) mediated transcription, ... 06/08/06 - 20060121013 - Use of negative regulatory elements for the neurospecific expression of transgenes The invention concerns novel methods and constructs for controlling nucleic acid expression, in particular methods and constructs using NRSE sequences for obtaining a targeted expression of transgenes in nerve cells. ... 06/08/06 - 20060121012 - Medical device with coating for capturing genetically-altered cells and methods of using same Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene ... 06/08/06 - 20060121011 - Combination gene delivery vehicles The combination of multiple, i.e., two or more, gene delivery vehicles (“GDVs”) with a pharmaceutically acceptable carrier or diluent to provide a pharmaceutically acceptable composition, and the administration of such a composition to an animal. The invention provides numerous advantages over previous methods of treating diseases or other pathogenic agents ... 06/08/06 - 20060121010 - Chorionic gonadotropin dna vaccines and methods The invention relates to immunotherapy of a mammalian subject by exposing the immune response cells of the subject to a nucleic acid construct encoding at least one hCG immunogenic epitope or precursor thereof such that the nucleic acid construct is taken up and processed by the immune response cells. The ... 06/08/06 - 20060121009 - Apparatus and method for machining michrochamber for cell culture A method for producing competent gene products in human cells, said method comprising the following steps: Providing a DNA construct in which a gene encoding a protein of interest is operably linked to a modified heat-inducible promoter, Introducing said DNA construct into a human cell line, either by transformation or ... 06/08/06 - 20060121008 - Primarily cultured adipocytes for gene therapy The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo ... 06/01/06 - 20060115464 - Use of cardiotrophin to modulate stem cell proliferation Methods of promoting stem cell proliferation by contacting the cells with cardiotrophin-1 (CT-1) are provided. The methods may further include contacting the stem cells with one or more stem cell modulators that promote differentiation of the stem cells. Methods of inhibiting stem cell proliferation by contacting the cells with one ... 06/01/06 - 20060115463 - Mixed-cell gene therapy The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been ... 06/01/06 - 20060115462 - Direct dna delivery to bone cells An method is described that enables in vivo delivery of polynucleotides to cells of a mammalian bone limb. The method involves the injection of polynucleotides in a large volume into the lumen of the bone. ... 06/01/06 - 20060115461 - Apparatus and system having dry gene silencing compositions A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least a first siRNA which ... 06/01/06 - 20060115460 - Compositions and methods comprising wnt proteins to promote repair of damaged tissue Compositions and methods for treating damaged tissue are provided herein. ... 05/25/06 - 20060110377 - Immunologically privileged cells and uses thereof The invention is directed to immunologically privileged cells, e.g., autologous, allogeneic, and xenogeneic intermediate lobe pituitary cells, for delivering polypeptides, e.g., insulin, to a subject, and to methods of using the same. ... 05/25/06 - 20060110376 - Mda-7 and free radicals in the treatment of cancer The present invention relates to methods of treating a cancer in a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. The present invention further relates to methods of inhibiting proliferation or ... 05/25/06 - 20060110375 - Method for producing cell lines and organs by means of differentiable cells A method for producing cell lines or individual organs, differentiable donor cells being supplied to a morula or blastocyst which is cultivated under conditions that ensure a further development of the morula or blastocyst in stages in which newly formed cell lines having a higher degree of differentiation occur, as ... 05/18/06 - 20060104964 - Recombinant sequence, its preparation and use An isolated, purified or recombinant nucleic acid sequence is disclosed, comprising: (a) a sequence that encodes both an angiogenic factor antagonist and a vascular endothelial structure regulator; (b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or (c) a sequence substantially homologous to or ... 05/18/06 - 20060104963 - Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells Transfected, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin− HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells express the cell surface antigen CD31. The transfected stem cells express an ... 05/18/06 - 20060104962 - Transfected hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith Transfected, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin−HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye and a gene operably encoding an antiangiogenic fragment of tryptophanyl tRNA synthetase (TrpRS). Preferably at least about 20% of the cells ... 05/18/06 - 20060104961 - Mechanisms of myoblast transfer in treating heart failure Bioengineering the regenerative heart provides a novel treatment for heart failure. On May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine ... 05/11/06 - 20060099195 - Tumor cells with increased immunogenicity and uses therfor Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using ... 05/11/06 - 20060099194 - Composition and method for clusterin-mediated stem cell therapy for treatment of atherosclerosis and heart failure Methods and compositions are disclosed for inhibiting, deterring or preventing apoptosis of cardiac myocytes, transplanted stem cells, vascular stem cells, and vascular smooth muscle cells by means of expressing or synthesizing clusterin. Also disclosed are methods and compositions for producing recombinant clusterin, or its biologically active peptides, and for induction ... 05/11/06 - 20060099193 - Methods and materials for suppressing pain Disclosed herein are methods and materials for suppressing pain that involve the production and implantation of stem cells genetically engineered to express pain suppression proteins. Specifically disclosed is a method of implanting mesenchymal stem cells engineered to express preproenkephalin. ... 05/04/06 - 20060093590 - Pseudotyped retroviruses Pseudotyped retroviruses having viral glycoproteins with modified O glycosylation regions are provided. Also provided are methods for making the pseudotyped retroviruses of the present invention and for using the pseudotyped retroviruses for transduction of target cells. Cells for stably producing the pseudotyped retroviruses or the present invention are also provided. ... 05/04/06 - 20060093589 - Vp2-modified raav vector compositions and uses therefor Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, ... 04/27/06 - 20060088512 - Treatment of t cell disorders The present invention relates to a method for treating a T cell disorder in a subject involving disrupting sex steroid signaling to the thymus and introducing into the subject bone marrow or haemopoietic stem cells (HSC). ... 04/27/06 - 20060088511 - Cancer therapy sensitizer The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of ... 04/20/06 - 20060083722 - Methods and compositions for cell therapy Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human mammal transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate ... 04/13/06 - 20060078545 - Neural progenitor cell populations This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in ... 04/13/06 - 20060078544 - Novel cancer-associated antigens and methods of their identification and use The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine ... 04/13/06 - 20060078543 - Neural progenitor cells derived from embryonic stem cells The present invention relates to undifferentiated human embryonic stem cells, methods of cultivation and propagation and production of differentiated cells. In particular it relates to the production of human ES cells capable of yielding somatic differentiated cells in vitro, as well as committed progenitor cells such as neural progenitor cells ... 04/06/06 - 20060073128 - Means and methods for the modulation of arteriogenesis The present invention relates generally to the modulation of arteriogenesis and/or the growth of collateral arteries or other arteries from preexisting arteriolar connections. In particular, the present invention provides a method for enhancing arteriogenesis and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting an ... 04/06/06 - 20060073127 - Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to rna interference molecules The present invention, at least in part, relates to the discovery of efficacious delivery of an RNAi agent (in preferred aspects of the invention, an siRNA) to a transplantable tissue. Organ rejection, transplantation-mediated transmission of viral infection, and triggering of apoptosis in transplanted tissues can each be minimized by the ... 04/06/06 - 20060073126 - Cytotoxic t lymphocyte The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte. ... 04/06/06 - 20060073125 - Isolation and use of solid tumor stem cells A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give ... 04/06/06 - 20060073124 - Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue Methods for the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, this invention relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that the cell is positive for the following markers: CD9, CD10, CD13, ... 04/06/06 - 20060073123 - Adenovirus vectors for immunotherapy The present invention provides compositions, methods and kits comprising viral vectors that may be used for performing immunotherapy. In particular, the present invention provides viral vectors having subgroup B adenoviral capsid fibers that are configured to express a transgene sequence in antigen presenting cells (e.g. dendritic cells) with a high ... 03/30/06 - 20060067920 - Chimeric immunoreceptor useful in treating human cancers The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of ... 03/30/06 - 20060067919 - Colon cancer metastasis inhibitor The present invention provides an agent for inhibiting metastasis of colorectal cancer and a method for inhibiting metastasis of colorectal cancer, which inhibit the function of Asef (i.e., binding activity to the APC gene product or guanine nucleotide exchange factor activity) that binds to the gene product of the tumor ... 03/23/06 - 20060062772 - Polypeptide delivery system An expression construct is disclosed which is useful for delivering an exogenous polypeptide (e.g. a growth hormone such as somatotropin) to a host. In one application of the invention, the expression construct is introduced into a non-host recombinant cell encapsulated in a semi-permeable membrane for implantation into the host. The ... 03/16/06 - 20060057130 - Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells or macrophage) that have been loaded with RNA derived from tumors or pathogens. By administering the RNA-loaded antigen-presenting cells to a ... 03/16/06 - 20060057129 - Preloaded dendritic cell vaccines for treating cancer This disclosure provides a technology for making a dendritic cell vaccine suitable for high volume manufacturing and distribution. Human stem cells are differentiated in a multi-step protocol to generate cell populations bearing a dendritic cell phenotype. The cells are loaded by pulsing with a specific tumor antigen, or by activation ... 03/16/06 - 20060057128 - Intradiscal injection of autologous interferon Administering to a patient Type I interferon or viable cells induced to produce Type I Interferon preferably into an inflamed joint, such an interverebral disc, for example, is disclosed. ... 03/16/06 - 20060057127 - Cytokine-expressing cellular vaccines for treatment of prostate cancer Genetically modified cytokine-expressing cells for use as vaccines in the treatment of prostate cancer are provided. More specifically, genetically modified, GM-CSF expressing cells as a means to generate an enhanced immune response to beta filamin and the use thereof in the treatment of prostate cancer are described. ... 03/09/06 - 20060051335 - Compositions and methods for elimination of unwanted cells Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium ... 03/09/06 - 20060051334 - Injection of bone marrow-derived conditioned medium for angiogenesis Methods are provided for promoting formation of collateral blood supply at an ischemic site in tissue by culturing early attaching cells derived from growth of bone marrow aspirate in vitro, collecting early attaching cells produced by the bone marrow culture and injecting conditioned medium produced by culture of the early ... 03/09/06 - 20060051333 - Aav virions with decreased immunoreactivity and uses therefor Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2. ... 03/09/06 - 20060051332 - Generation of histocompatible tissues using nuclear transplantation Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy. ... 03/09/06 - 20060051331 - Optimization of transgene expression in mammalian cells The present invention relates to vectors, compositions and methods for delivering transgenes into mammalian cells. The invention also relates to genetic constructs and recombinant cells suitable to produce such transgenes. The invention more particularly relates to a vector suitable for transgene delivery into mammalian cells, wherein said vector comprises a ... 03/09/06 - 20060051330 - Method for carrying out the ex vivo expansion and ex vivo differentiation of multipotent stem cells The invention relates to a method for carrying out the expansion of multipotent stem cells ex vivo. Moreover, the invention relates to a two-stage method for carrying out the expansion and differentiation of multipotent stem cells ex vivo, in which it is possible for the stem cells to be gene ... 03/02/06 - 20060045873 - Induction of methylation of cpg sequences by dsrnas in mammalian cells The present inventors found that in human cells, synthetic small interfering RNAs (siRNAs) targeted to a region containing the CpG islands on gene promoters will specifically induce the methylation of CpG sequences within the target region or adjacent regions. Methylation of the promoters results in suppression at a transcriptional level ... 02/23/06 - 20060039897 - Stinging cells expressing an exogenous polycleotide encoding a therpeutic, diagnostics or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derive therefrom for delivering the therapeutic, diagnostic or cosmet A stinging cell comprising an exogenous polynucleotide capable of expressing a therapeutic, cosmetic or diagnostic agent in the stinging cell is provided. ... 02/16/06 - 20060034813 - Expression of proteins in cord blood-derived endothelial cells The invention provides a population of mature endothelial cells derived from human cord blood. The cells can be transduced with DNA encoding a therapeutically effective protein such as a blood coagulation factor. The cells are useful in a method for the production of a blood coagulation factor. They can further ... 02/16/06 - 20060034812 - Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect A method for treating tumors. Through infusion or xenotransplantation of xenogeneic cells, such as infusion of murine cells into the peritoneal cavity of humans, a hyperacute rejection response to the cells is induced. This in turn creates a bystander effect to the tumor. This effect creates tumor regression. This treatment ... 02/16/06 - 20060034811 - Melanoma vaccine and methods of making and using same An immunotherapeutic vaccine providing antigen presenting cells that have been pulsed with a disrupted cell preparation which includes enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment, the vaccine includes autologous dendritic/monocytic cells (DC/M) that ... 02/16/06 - 20060034810 - Novel artificial antigen presenting cells and uses therefor The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of ... 02/09/06 - 20060029584 - Methods for improving cell line activity in immunoisolation devices Methods for maintaining and improving the secretory activity of cells housed in immunoisolation devices. ... 02/09/06 - 20060029583 - Method for the genetic activation of cells and uses of said cells Mammalian cells, normally dependent of IL-2, can be successfully transfected to express IL-2 in amounts sufficient to sustain growth without the external addition of IL-2. One cell line expressing IL-2 solely in the endoplasmatic reticulum without secretion, and one cell line capable of secretion of IL-2 have been developed and ... 02/09/06 - 20060029582 - Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapy The invention provides methods of treating neoplasia using combinations of target cell-specific replication competent adenoviral vectors and chemotherapy, radiation therapy or combinations thereof. The adenoviral vectors are target cell-specific for the particular type of neoplasia for which treatment is necessary and the combination with the chemotherapy and/or radiation leads to ... 02/02/06 - 20060024280 - Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis The present invention provides cloned, genetically modified, endothelial cells, and the stem cells from which they are derived, which are produced by somatic cell nuclear transfer. The invention further provide novel therapeutic methods in which such cells are administered to a patient with tumors to inhibit and/or disrupt angiogenesis of ... 02/02/06 - 20060024279 - Retroviral vectors Retroviral vector particles having an RNA genome carrying sequences which provide in the DNA provirus at least one selected gene located within an intron in a transcription unit of the provirus, which transcription unit further comprises a polynucleotide response element responsive to a nucleus to cytoplasm transport factor such as ... 02/02/06 - 20060024278 - Methods and products related to the production of inner ear hair cells The invention relates to the generation of inner ear sensory epithelial cells through the manipulation of the expression level or function of the genes and/or proteins involved in the retinoblastoma (Rb) pathway, particularly retinoblastoma family members, such as Rb1. Methods for generating inner ear sensory epithelial cells and for restoring ... 01/26/06 - 20060018889 - Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy The present invention provides an isolated nucleic acid comprising a promoter operably linked to a nucleic acid encoding a peptide or protein and/or an RNA (e.g., antisense or ribozyme), wherein the promoter comprises elements that can include, but are not limited to, a) a myeloid specific promoter element comprising a ... 01/26/06 - 20060018888 - Suicidal mutant leishmania vaccine The present invention discloses the use of a mutant Leishmania as a suicidal vaccine wherein the mutant Leishmania is responsive to external signals to become porphyric and commit suicidal cytolysis. The mutant can be selected from natural Leishmania species or constructed by genetic engineering. ... 01/19/06 - 20060013805 - Transgenic circulating endothelial cells A process is provided for expanding the population of endothelial cells obtained from peripheral blood which can be transformed with a vector comprising a DNA sequence encoding a preselected bioactive polypeptide. The resulting transgenic endothelial cells are useful to biocompatibilize implantable medical devices or can be used directly, as for ... 01/12/06 - 20060008452 - Mesenchymal precursor cell A method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of ... 01/12/06 - 20060008451 - In vivo methods for effecting tissue specific differentiation of embryonic stem cells Methods for producing derived differentiated cells from chimeric animals, fetuses and embryos derived from non-human chimeric embryos are provided. These non-human chimeric embryos are obtained by introduction of at least one transgenic ES or ES-like cell into a recipient non-human embryo, e.g., blastocyst stage embryo, wherein said ES or ES-like ... 01/12/06 - 20060008450 - Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells in cardiac indications. ... 01/12/06 - 20060008449 - Device and methods for treatment of necrotic tissue using stem cells Devices and methods for precisely directing a dosage of therapeutic substance are disclosed. The devices include an elongated shaft member, a deployable needle associated with the elongated shaft member, an injection reservoir in fluid communication with the deployable needle; and means associated with the deployable needle for displacing the distal ... 01/05/06 - 20060002906 - Tolerizing allografts of pluripotent stem cells This disclosure provides a system for overcoming HLA mismatch between an allograft derived from stem cells, and a patient being treated for tissue regeneration. A state of specific immune tolerance is induced in the patient, by administering a population of tolerizing cells derived from the stem cells. This allows the ... 01/05/06 - 20060002905 - Mutant forms of etxb and ctxb and their use as carriers The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB. ... 01/05/06 - 20060002904 - Receptor and related products and methods The human receptor H4-1BB has been isolated, sequenced and disclosed herein. The cDNA of the human receptor H4-1BB is about 65% homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB ... 12/29/05 - 20050287130 - Methods of modifying cell structure and remodeling tissue Disclosed is a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under conditions effective to modify the structure of the mammalian cell. Also disclosed are methods of performing in vivo tissue remodeling in a ... 12/29/05 - 20050287129 - Vectors and methods for long-term immune evasion to prolong transplant viability Vector compositions and methods are provided for transfecting donor cell populations and tissues for grafts, for reducing expression of mismatched proteins, thereby reducing immunogenicity of the grafted cells and tissues in a recipient subject. ... 12/29/05 - 20050287128 - Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating TGF-beta and/or TGF-betaR gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of TGF-beta and/or TGF-betaR gene ... 12/29/05 - 20050287127 - Use of stem cells to generate inner ear cells This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear. ... 12/22/05 - 20050281791 - Method for inducing cardiac myocytes in embryonic stem (es) cells by induction with precardiac endoderm and mesoderm A method to induce ES cells to the cardiac phenotype is disclosed whereby avian precardiac endoderm used as feeder/inducer cells induce high percentage conversion of mouse embryonic stem (mES) cells into cardiac myocytes. Upon induction, the majority (˜65%) of co-cultured ES cell-derived embryoid bodies (EBs) become enriched in cardiac myocytes ... 12/08/05 - 20050271639 - Genetically engineered cells for therapeutic applications An isolated mesenchymal stem cell, multipotent adult progenitor cell, or other stem cells is genetically modified to express at least one of CXCR4, SDF-1, or a variant thereof. ... 12/08/05 - 20050271638 - Bmp pathway methods and compositions The present invention relates to mutant BMP intestinal stem cells (ISCs), with these mutant ISCs possessing an inactive Bmpr1a receptor in which BMP binding is substantially inhibited. The present invention relates to vectors which comprise mutant Bmpr1a nucleic acid sequences, whereby the vectors can be used to promote an increase ... 12/08/05 - 20050271637 - Bmp-2 estrogen responsive element and methods of using the same The invention relates to an isolated nucleic acid corresponding to BMP-2 regulatory region, or a fragment thereof comprising an estrogen responsive element, vector comprising the same and cells, which comprises said vector. In another embodiment, the invention provides methods of identifying an estrogen agonist, antagonist and a therapeutic agent in ... 12/08/05 - 20050271636 - Diagnostic and therapeutic uses for prox 1 Methods and compositions based on the elucidation of the role of Prox1 in lymphatic tissue development in normal and tumor tissue are provided. Included are methods for determining the extent of lymphatic involvement in a tumor, methods for purifying endothelial precursor cells predisposed to develop into lymphatic tissue, and methods ... 12/01/05 - 20050265983 - Methods, nucleic acid constructs and cells for treating neurodegenerative disorders A method of treating a neurodegenerative disorder is provided. The method is effected by administering to an individual in need thereof cells capable of exogenously regulatable neurotransmitter synthesis thereby treating the neurodegenerative disorder. ... 11/24/05 - 20050260180 - Materials and methods for treating vascular leakage in the eye The invention is directed to a method of prophylactically or therapeutically treating an animal for vascular leakage in an eye. The method comprises administering to an animal in need thereof an expression vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) such that vascular leakage in the eye ... 11/24/05 - 20050260179 - Stem and progenitor cell capture for tissue regeneration A method for capturing stem cells and/or progenitor cells from circulating body fluids such as blood or lymph in vivo and enabling the cells to colonize a specific, localized site for purposes of tissue regeneration or repair, has been developed. The method consists of selecting a site in need of ... 11/24/05 - 20050260178 - Delivery of an organized tissue to an organism A sleeve organized tissue is formed of a biocompatible structure surrounding organized tissue in at least one dimension and along a length of the tissue. In certain preferred embodiments the tissue is attached to the sleeve, subjecting the organized tissue to internal tension within the sleeve. Methods of providing organized ... 11/10/05 - 20050249711 - Allogeneic vaccine and methods to synthesize same This invention provides a genetically manipulated cell useful for treating or preventing a malignant tumor in a patient which: (a) expresses at least one immunomolecule selected from the group consisting of cytokines, adhesion molecules, costimulatory factors, tumor associated antigens and tumor specific antigens; and (b) is allogenic to the patient. ... 11/03/05 - 20050244388 - Suprabasal breast cell with stem cell properties A method for isolating cells which have a suprabasal position and expresses epithelial specific antigen but no sialomucin is provided. The isolated cells are shown to share many of the properties expected of a mammary gland stem cell. Three permanent cell lines that are capable of proliferating and capable of ... 10/27/05 - 20050238629 - Lentiviral ltr-deleted vector A vector capable of transducing non-dividing and/or slowly dividing cells is provided, wherein the vector is a lentiviral LTR-deleted vector. Also provided is a method for producing a protein of interest in a non-dividing or slowly dividing cell by transducing the cell with a lentiviral LTR-deleted vector and expressing the ... 10/27/05 - 20050238628 - Methods for treating cancer The present invention relates to methods and compositions for treating cancer and related diseases. ... 10/27/05 - 20050238627 - Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer The present invention relates to methods for treating and preventing cancer and for treating precancerous lesions by administering a therapeutically effective dose of a vaccine comprising fusion cells formed by fusion of antigen presenting cells and non-dendritic cells that contain genomic DNA or cDNA derived from a tumor cell or ... 10/27/05 - 20050238626 - Antigen specific t cell therapy Provided are methods for generating immune cells of the desired type and specificity in a host. The methods may be used to treat a disease or disorder, such as a tumor in a patient. Target cells, preferably hematopoietic stem cells such as primary bone marrow cells are transfected with a ... 10/27/05 - 20050238625 - Muscle-derived cells (mdcs) for promoting and enhancing nerve repair and regeneration The present invention describes methods involving the use of muscle derived cells (MDCs), preferably obtained from skeletal muscle, to support the innervation and repair of damaged tissues and organs, particularly associated with nerve damage or neuropathy. The invention relates to MDCs for use in methods for promoting or enhancing innervation ... 10/27/05 - 20050238624 - Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications Composition and method for stimulating angiogenesis, stimulating myogenesis, upregulating angiogenic factors and angiopoietins, and treating the muscular and vascular complications of diabetes. Overall, the embodiments of the invention can be accomplished by delivering a heterologous nucleic acid sequence encoding insulin-like growth factor I (“IGF-I”) or a functional biological equivalent thereof ... 10/20/05 - 20050232907 - Use of herpes vectors for tumor therapy Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) ... 10/20/05 - 20050232906 - Adjuvant preparation for the induction of specific immunity Disclosed are methods and compositions useful in the recruitment, activation and initiation of proliferation of immune cells. The instant invention relates to the discovery that specific insect cells and insect cell compositions exhibit adjuvant properties. The added benefit of this system is that the insect cells utilized may be transformed ... 10/20/05 - 20050232905 - Use of peripheral blood cells for cardiac regeneration The present invention concerns methods of improving cardiac function in cardiac tissues of a recipient host by delivery of peripheral blood derived stem cells. The present invention also describes methods of stimulating cardiac tissue regeneration in a recipient host. Methods of treating a diseased cardiac tissue in a recipient host, ... 10/20/05 - 20050232904 - Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance A method of inducing tolerance to a transplant transplanted from a donor to a recipient is disclosed. The method comprises (a) culturing a hematopoietic progenitor cell (HPC) population under growth conditions suitable for inducing or enhancing veto activity in at least a portion of the HPC population, thereby generating a ... 10/06/05 - 20050220775 - Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo ... 10/06/05 - 20050220774 - Methods of inducing differentiation in ex vivo expanded stem cells Method of differentiating ex vivo expanded stem cells in-tissue anti in vivo are provided. Also provided are method of treating individuals suffering from a disorder necessitating cell replacement or tissue replacement therapy using ex vivo expanded stem cells. ... 10/06/05 - 20050220773 - Implant containing cells having growhfactor gene transferred thereinto This invention provides alternative bone implants that have high bioadaptability and enable rapid bone regeneration. Specifically, this invention relates to implants consisting of a bioadaptable material comprising cells transfected with growth factor genes. Such implants are produced by inoculating bone-marrow-derived cells transfected with the genes of vascular endothelial growth factors ... 10/06/05 - 20050220772 - Stem cell screening and transplantation therapy for hiv infection This invention provides methods for preventing or treating any disease arising from HIV infection, including AIDS and AIDS-related complex (ARC). The method comprises screening a plurality of donors to identify stem cells with a beneficial gene or genes and then transplanting the therapeutic stem cells into a patient. In preferred ... 09/29/05 - 20050214269 - Induction of beta cell differentiation in human cells The present invention provides methods for inducing insulin gene expression in cultured pancreas cells, the method comprising contacting a culture of endocrine pancreas cells expressing a PDX-1 gene and a NeuroD/BETA2 gene with a GLP-1 receptor agonist, wherein the cells have been cultured under conditions such that the cells are ... 09/29/05 - 20050214268 - Methods for treating tumors and cancerous tissues The invention disclosed herein relates generally to immunotherapy and, more specifically, to therapeutic methods for treating tumors and cancerous tissues by first inducing necrosis or apoptosis (e.g., cryotherapy, chemotherapy, radiation therapy, ultrasound therapy, or a combination thereof applied against at least a portion of the tumor or cancerous tissue), and ... 09/29/05 - 20050214267 - Compositions and methods for controlling insects related to the octopamine receptor A screening method for identifying compounds that are effective insect control agents includes providing cells expressing an octopamine receptor, adding the compounds to the cells, and measuring the effects of the compounds and compositions. The effects of the compounds may be determined by measuring the binding affinity of the compounds ... 09/29/05 - 20050214266 - Combination of transplantation and oncolytic virus treatment Oncolytic viruses can be used to purge cellular compositions to remove undesired neoplastic cells before the cellular compositions are used for transplantation. The present invention relates to the use of a virus to pre-treat a subject prior to delivery into the subject a transplant that has been purged with the ... 09/29/05 - 20050214265 - Method for improving bone marrow engraftment The present invention demonstrates that a delay in marrow infusion is associated with a decrease in the amount of conditioning required and improved engraftment. Surprisingly, it has been discovered that for a given dose of TBI, a delay in transplantation of the marrow for up to 8 days, and preferably ... 09/29/05 - 20050214264 - Sacromastigophoric therapeutic agent delivery system A sacromastigophoric organism such as a trypanosome is harnessed for its ability to evade a host immune system, as well as its vast carrying capability to deliver a therapeutic agent to a host. The organism is engineered to include a recombinant lytic factor. After administration of the live organism to ... 09/29/05 - 20050214263 - Methods and means for gene silencing in plants Provided are methods of silencing a target gene in an organism, which methods comprises the steps of: (a) providing a recombinant DNA construct including an expression cassette comprising: (i) a promoter, operably linked to, (ii) a chimeric nucleotide sequence encoding all or part of the target gene and a transgene, ... 09/22/05 - 20050208032 - Oral administration of therapeutic agent coupled to transporting agent The present invention is directed toward a composition for widespread distribution, systemic expression and sustained delivery of a therapeutic or transdifferentiating agent and to a process for administration of said agent via a natural gastrointestinal pathway. More particularly, the invention discloses a composition for the administration of oral gene therapy ... 09/22/05 - 20050208031 - Inhibition of calcium-independent phospholipases a2beta or a2gamma inhibit hormone-induced differentiation of 3t3-l1 preadipocytes A method for identifying an agonist exhibiting molecular or pharmacologic inhibition which is effective against the activity of at least one of iPLA2β and iPLA2γ which comprises culturing 3T3-L1 cells and transfecting them with negative control siRNA, siRNA directed against iPLA2β or siring directed against iPLA2γ prior to induction or ... 09/22/05 - 20050208030 - Myocardial grafts and cellular compositions useful for same Described are preferred myocardial grafts of skeletal myoblasts or cardiomyocytes, and cellular compositions and methods useful in obtaining the grafts. The myocardial grafts are stable and can be used, for example, to deliver recombinant proteins directly to the heart. ... 09/22/05 - 20050208029 - Method of forming pancreatic beta cells from mesenchymal cells It is intended to provide a method of forming pancreatic β cells from mesenchymal cells characterized by comprising using mammal-origin mesenchymal cells as starting cells, culturing these cells in the presence of, for example, a pancreatic β cell-forming agent, and selecting and separating the thus obtained pancreatic βcells with the ... 09/15/05 - 20050201995 - Methods and compositions related to neuronal differentiation Compositions and methods of the invention use a novel transactivator methodology for manipulation of the molecular mechanisms of cell determination for the production of a cell with a neuronal phentoype. A recombinant transcription factor or transactivator that binds the RE1 promoter element, REST-transactivator, was constructed by replacing the repressor domains ... 09/15/05 - 20050201994 - Human ctla-4 antibodies and their uses The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. ... 09/15/05 - 20050201993 - Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization ... 09/15/05 - 20050201992 - Tumor/b-cell hybrid cells and uses thereof The present invention is directed to methods and compositions for slowing or inhibiting the growth of tumors and decreasing the size of existing tumors. The compositions include dendritic cells contacted with tumor/B-cell hybrid cells and various T-cells contacted with tumor/B-cell hybrid cells (TBH cells). The present invention further encompasses methods ... 09/15/05 - 20050201991 - Stem cell culture We describe a method to manipulate the phenotype of stem cells, preferably embryonic stem cells (ES), including nucleic acids and vectors used in said methods. ... 09/01/05 - 20050191285 - Compounds for eliciting or enhancing immune reactivity to her-2/neu protein for prevention or treatment of malignancies in which the her-2/neu oncogene is associated Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated. ... 09/01/05 - 20050191284 - Mammalian common lymphoid progenitor cell A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for lymphoid lineages, but lacking the potential to differentiate into myeloid and erythroid lineages. Methods are provided for the isolation and culture of this common lymphoid progenitor cell (CLP). The cell enrichment methods employ ... 09/01/05 - 20050191283 - Methods of treating nfat-related disorders The invention provides, among other things, methods for modulating NFATc2 and methods for treating graft versus host disease, transplant rejection, and other NFATc2-related disorders. ... 08/25/05 - 20050186187 - Methods for protein production Methods for altering the cellular secretion rate of a protein, such as an antibody and the altered cells produced by the method are disclosed. The methods and altered cells are useful for producing high levels of proteins for therapeutic, diagnostic or research purposes. ... 08/25/05 - 20050186186 - Compositions for eliciting immune response and methods for using same A tumor cell having DcR3/TR6 anchored at its surface, a composition comprising same and methods comprising same which may advantageously be used to elicit an immune response in a patient in need thereof. ... 08/25/05 - 20050186185 - Room temperature storage of organs The present invention relates generally to compositions and method for freezing and/or drying organs for storage prior to use. In particular, the present invention relates to the genetic modification of cells used to form organs so that organs formed from the genetically modified cells can be dried. According to the ... 08/25/05 - 20050186184 - Mammalian pluripotent neural cells and uses thereof The present invention discloses the identification and characterization of a novel mammalian pluripotent neural cell population. More particularly, the present invention relates to compositions and methods allowing the identification, monitoring, culture and differentiation of boundary cap cells and their progeny. The invention also relates to methods of screening compounds that ... 08/18/05 - 20050180960 - Alginate capsules for use in the treatment of brain tumour Encapsulated producer cells which are capable of expressing a molecule which is an inhibitor of CNS tumour growth provide a novel approach to the treatment of tumours, such as brain tumours which are localized within the central nervous system. ... 08/18/05 - 20050180959 - Kinases involved in the regulation of energy homeostasis The present invention discloses Inositol hexakisphosphate kinase or RYK kinase homologous proteins regulating the energy homeostasis and the metabolism of energy storage metabolites, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, ... 08/11/05 - 20050175596 - Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been ... 08/04/05 - 20050169900 - Allogeneic vaccine and methods to synthesize same This invention provides a retroviral vector comprising (a) a 3′LTR; and (b) an insert having (i) a promoter, (ii) a sequence encoding an immunomolecule selected from the group consisting of cytokines, adhesion molecules, costimulatory factors, tumor associated antigens and tumor specific antigens, and (iii) a poly A signal, respectively, said ... 08/04/05 - 20050169899 - Peptide scaffolds for transfer of molecules into eukaryotic cells Compositions and methods of using compositions with a nuclear targeting peptide containing a nonclassical nuclear localization signal to deliver selected molecules to the nucleus of eukaryotic cells are provided. The compositions are particularly useful in gene transfer methods. ... 08/04/05 - 20050169898 - Cell fusions and methods of making and using the same The invention is concerned with fusions of dendritic cells and antigen presenting cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy. The fusions according to the invention can also be used in methods for antigen discovery. ... 08/04/05 - 20050169897 - Engraftable neural progenitor and stem cells for brain tumor therapy One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and ... 07/28/05 - 20050163763 - Induction of beta cell differentiation in human cells by stimulation of the glp-1 receptor The present invention provides methods for inducing insulin gene expression in cultured pancreas cells, the method comprising contacting a culture of endocrine pancreas cells expressing a PDX-1 gene with a GLP-1 receptor agonist, wherein the cells have been cultured under conditions such that the cells are in contact with other ... 07/28/05 - 20050163762 - Targeting antigen-specific t cells for specific immunotherapy of autoimmune disease Antigen-specific T cells are stimulated to proliferate by activation with properly presented antigen. Targeting a detrimental product to only those cells which are stimulated to proliferate in response to the antigen presentation permits the selective and highly efficient ablation of a key component of the disease symptomology of myasthenia gravis. ... 07/28/05 - 20050163761 - Agent for inducing or inhibiting an angiogenesis The invention relates to an agent for inducing or inhibiting angiogenesis, to a method for the production thereof and to the use thereof. ... 07/28/05 - 20050163760 - Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders The present invention provides novel methods for delivering cells, particularly modified cells to the central nervous system (CNS). The purpose of this invention is to present a method that provides sustained delivery of a molecule to the central nervous system, thereby increasing the bioavailability of the molecule and lengthening the ... 07/21/05 - 20050158289 - Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers is provided, as well as enriched populations of mesenchymal precursor cells and compositions comprising the cells. The markers may be either i) the presence of markers specific for mesenchymal precursor ... 07/21/05 - 20050158288 - Methods of organ regeneration The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type ... 06/30/05 - 20050142122 - Brassica plant resistant to the fungus leptosphaeria maculans (blackleg) The invention relates to fungal disease resistance, in particular to resistance to blackleg disease caused by Leptosphaeria maculans. Provided are Brassica plants and seeds comprising a fragment of chromosome 8 of a wild B. rapa accession in their genome, wherein this fragment comprises a blackleg resistance locus. Further provided are ... 06/30/05 - 20050142121 - System for improving acceptance of tissue grafts made from embryonic stem cells This disclosure provides a system for improving survival of cells obtained by differentiating human embryonic stem cells, upon transplantation into a subject for regenerative medicine. Transplanted cells that don't survive normally send out signals that exacerbate the rejection response of the host, which in turn leads to further cell destruction. ... 06/30/05 - 20050142120 - Cells expressing anti-fc receptor binding components Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an ... 06/23/05 - 20050136042 - Methods and compositions for tissue repair Methods and compositions for tissue repair are provided. The methods involve obtaining tissue from a patient, including for example, muscle or fat tissue, and contacting the tissue with one or more bioactive agents to induce at least a portion of the cells in the tissue to differentiate into cells of ... 06/23/05 - 20050136041 - In vivo production and delivery of erythropoietin or insulinotropin for gene therapy The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1 (GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material ... 06/23/05 - 20050136040 - Control of gene expression using a complex of an oligonucleotide and a regulatory peptide A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an ... 06/16/05 - 20050129673 - Chondrocyte cell-lines The invention relates to chondrocytes and chondrocyte cell-lines for use especially in studying arthritic conditions and also for developing skeletal tissue for use in repair and/or replacement surgery. The use of articular chondrocyte cell-lines which mineralise calcium to determine potentially beneficial therapeutic agents is disclosed. Further, the means for producing ... 06/16/05 - 20050129672 - Regulatory sequences that direct gene expression to spinal motor neurons and uses thereof The present invention relates to an enhancer which functions only in human brain and/or spinal cord motor neurons, where the enhancer comprises a nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 10, or SEQ ID NO: 16. The enhancer can be utilized as part of a nucleic acid ... 06/16/05 - 20050129671 - Mammalian antigen-presenting t cells and bi-specific t cells The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to viral specific T cells that express chimeric anti-tumor receptors. These bi-specific T cell clones are a source of effector cells that persist in vivo in response ... 06/16/05 - 20050129670 - Tumor cells modified to express b7-2 with increased immunogenicity and uses therefor Tumor cells modified to express one or more T cell costimulatory molecules are disclosed. Preferred costimulatory molecules are B7-2 and B7-3. The tumor cells of the invention can be modified by transfection with nucleic acid encoding B7-2 and/or B7-3, by using an agent which induces or increases expression of B7-2 ... 06/16/05 - 20050129669 - Dna construct for effecting homologous recombination and uses thereof The invention relates to constructs comprising: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) an unpaired splice-donor site. The invention further relates to a method of producing protein in vitro or in vivo comprising the homologous recombination of a construct as described above within a ... 06/09/05 - 20050123526 - Administration of growth factors for neurogenesis and gliagenesis Devices and methods for treating diseases associated with loss of neuronal function by cell replacement therapy are described. The methods are designed to promote proliferation, differentiation, migration, or integration of exogenous stem cells transplanted into the central nervous system (CNS). A therapy, such as an electrical signal or a stem ... 06/09/05 - 20050123525 - Composition and method for inducing immune tolerance towards cell, tissue and/or organ transplants The present invention relates to a composition comprising embryonic stem cells or haematopoietic stem cells or precursor cells being obtained by differentiation of said embryonic stem cells as well as trophoblasts, trophoblasts precursor and/or placental cell derived from said trophopblasts, all cell types being derived from the same embryonic stem ... 06/09/05 - 20050123524 - Pharmaceutical compositions and methods for treating neuronal damages and neurodegenerative diseases Pharmaceutical compositions comprising Nedd9 protein are provided. The pharmaceutical compositions may further comprise FAK protein. These compositions can be used for the treatment of neuronal damages and neurodegenerative diseases. Methods for treating neuronal damages or neurodegenerative diseases are also provided. The methods comprise administering a composition comprising Nedd9 protein. Furthermore, ... 06/09/05 - 20050123523 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 06/09/05 - 20050123522 - Monocyte-derived dendritic cell subsets A novel subset of monocyte-derived dendritic cells are provided. Methods for producing these monocyte-derived dendritic cells and compositions comprising the dendritic cells of the invention are also provided. Methods for inducing an immune response to an antigen of interest using the dendritic cells of the invention are provided. Also provided ... 06/09/05 - 20050123521 - Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase Immortalized primary adult and fetal human cells are provided that express a functional telomerase catalytic subunit from a nucleic acid sequence encoding the hTERT gene. The telomerase-immortalized human cells can be maintained in culture for at least 35 population doublings without developing a transformed phenotype, and while continuing to express ... 06/02/05 - 20050118151 - Proteins in diabetes proteome anlysis Provided are mammalian secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable ... 06/02/05 - 20050118150 - Methods of controlling proliferation and differentiation of stem and progenitor cells A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells. The method comprises ex-vivo providing the stem cells with conditions for cell proliferation and with at least one copper chelator in an amount and for a time period for ... 06/02/05 - 20050118149 - Methods and compositions for modulating telomerase reverse transcriptase (tert) expression Methods and compositions are provided for modulating, and generally upregulating, the expression of telomerase reverse transcriptase (TERT) by blocking repression of TERT transcription, e.g., by inhibiting binding of repressor factor to a Site C repressor binding site located in the TERT minimal promoter. The subject methods and compositions find use ... 06/02/05 - 20050118148 - Compositions and methods related to mammalian maf-a Various embodiments of the invention include methods of generating a β-like cell comprising providing an expression cassette comprising a nucleic acid sequence encoding MafA under the control of a heterologous promoter and transferring the expression cassette into a non-insulin producing cell, wherein the expression of the MafA in the cell ... ### FreshPatents.com Support |